Figure 2.
High expression level of HGF and c-MET were indicators of unfavorable clinical outcome in gastric cancer. A. Overall survival of patients in HGF-low expression group and HGF-high expression group based on TCGA database. B. Overall survival of patients in c-MET-low expression group and c-MET-high expression group based on TCGA database. C. Overall survival of patients in both of HGF and c-MET low expression group and both of HGF and c-MET high expression group based on TCGA database. D. Progression-free survival of patients in HGF-low expression group and HGF-high expression group based on TCGA database. E. Progression-free survival of patients in c-MET-low expression group and c-MET-high expression group based on GEO database. F. Progression-free survival of patients in both of HGF and c-MET low expression group and both of HGF and c-MET high expression group based on GEO database. G. Overall survival of patients in HGF-low expression group and HGF-high expression group based on GEO database. H. Overall survival of patients in c-MET-low expression group and c-MET-high expression group based on GEO database. I. Overall survival of patients in both of HGF and c-MET low expression group and both of HGF and c-MET high expression group based on GEO database. The survival time of patients was compared between groups using the Mantel-Cox test.